Palomino Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	19.44	8.12	0.13	0.14
Cash & Short-Term Investments	19.44	8.12	0.13	0.14
Cash Growth	1028.12%	5931.21%	-3.49%	-
Prepaid Expenses	0.15	0.31	0	-
Total Current Assets	19.59	8.43	0.14	0.14
Total Assets	21.04	8.43	0.14	0.14
Accounts Payable	0.16	0.23	0	0
Accrued Expenses	0.15	0.09	-	-
Short-Term Debt	-	-	0	0
Other Current Liabilities	-	0.01	-	-
Total Current Liabilities	0.37	0.34	0.01	0.01
Other Long-Term Liabilities	-	-	0.15	0.14
Total Liabilities	0.48	0.34	0.16	0.14
Common Stock	0	0	0	0
Additional Paid-In Capital	26.35	11.28	-	-
Retained Earnings	-5.79	-3.18	-0.02	-0
Comprehensive Income & Other	-	-	-0	-
Shareholders' Equity	20.57	8.1	-0.02	-0
Total Liabilities & Equity	21.04	8.43	0.14	0.14
Total Debt	0.17	-	0	0
Net Cash (Debt)	19.28	8.12	0.13	0.14
Net Cash Growth	1020.42%	6075.20%	-3.57%	-
Net Cash Per Share	1.24	1.21	0.09	0.22
Filing Date Shares Outstanding	27.64	18.92	18.77	0.61
Total Common Shares Outstanding	23.16	18.77	6	0.61
Working Capital	19.22	8.1	0.13	0.13
Book Value Per Share	0.89	0.43	-0.00	-0.00
Tangible Book Value	20.57	8.1	-0.02	-0
Tangible Book Value Per Share	0.89	0.43	-0.00	-0.00